Selective Immunosuppression by Administration of Major Histocompatibility Complex Class II-binding Peptides. II. Preventive Inhibition of Primary and Secondary In Vivo Antibody Responses

By Jean-Charles Guéry, Monica Neagu, Gemma Rodriguez-Tarduchy, and Luciano Adorini

From Preclinical Research, Sandoz Pharma Ltd., CH-4002 Basel, Switzerland

Summary

The self-mouse lysozyme peptide corresponding to residues 46-62 (ML46-62) binds to the major histocompatibility complex (MHC) class II molecules I-A$^k$ and it selectively inhibits, when coinjected with antigen, priming of I-A$^k$-restricted, antigen-specific T cells. We demonstrate that administration of ML46-62 also inhibits in vivo antibody responses induced by I-A$^k$-restricted T helper cells. ML46-62 is able to prevent the primary anti-hen egg white lysozyme (HEL) antibody response induced by the entire HEL molecule in B10.A(4R) mice, expressing only I-A$^k$ molecules, but not in mice of H-2$d$ haplotype. ML46-62 also strongly decreases, in B10.A(4R) mice, the antibody response to ribonuclease A, a protein antigen unrelated to the MHC blocker, indicating that MHC blockade is the mechanism leading to inhibition of antibody response. This is further supported by the concomitant decrease, in vivo, of complex formation between immunodominant HEL peptides and I-A$^k$ molecules, preventing I-A$^k$-restricted T cell induction. Administration of ML46-62 after antigen priming does not affect ongoing antibody responses, as expected from MHC blockade. A single injection of ML46-62 at the time of protein antigen priming precludes not only the primary, but also the secondary antibody response to a subsequent challenge with soluble protein, even when the challenge is performed several months after priming. Coinjection of antigen and MHC antagonist inhibits production of all antibody isotypes equally well, suggesting that MHC class II blockade affects both Th1- and Th2-type T helper cells. Therefore, these results indicate that administration of MHC class II-binding peptides can efficiently and selectively prevent the induction of T cell-dependent primary and secondary in vivo antibody responses by blocking antigen presentation to class II-restricted T helper cells.

Peptides bound to class II MHC molecules on the surface of APCs are the ligands for antigen-specific receptors of CD$^+$ T cells (1). Each MHC class II molecule can bind different peptides, indicating that the interaction between peptide and MHC is a low degree of specificity (2). One consequence of the broad-range specificity of peptide–MHC interactions is that peptides of different sequences may compete for presentation by the same MHC molecule to T lymphocytes.

Peptide competition for antigen presentation has been demonstrated in vitro, by showing that antigens binding to the same MHC molecules can compete with each other for presentation to T cells (3-6). A direct correlation has been demonstrated between the capacity of a peptide to bind to purified MHC class II molecules and its ability to compete for presentation of antigenic peptides binding to the same class II molecules (7, 8). Peptide competition for the MHC class II binding site also occurs in vivo. This has been demonstrated first by competition between self- and non-self peptides for T cell activation, showing that T cell responses to antigenic peptides can be inhibited by coinjection of antigen and an unrelated MHC class II-binding competitor peptide (9). Subsequently, several groups have used a similar strategy to prevent induction of T cell–mediated autoimmune diseases like experimental allergic encephalomyelitis in mice (10, 11) and rats (12), or autoimmune carditis in mice (13).

These results suggest that in vivo competition for antigen presentation may result in MHC blockade preventing T cell activation. Recently, using an ex vivo system, we have demonstrated that lymph node cells (LNC)$^2$ from mice immunized with HEL (14) can directly compete with antigen binding to MHC class II molecules a T cell receptor, and that this competition can be inhibited by coinjection of an unrelated MHC class II–binding peptide (15). These results suggest that the inhibition of T cell responses by MHC class II–binding peptides may be a general mechanism for the prevention of T cell–mediated autoimmunity.

---

1 Abbreviations used in this paper: HEL, hen egg-white lysozyme; LNC, lymph node cells; RNase, bovine ribonuclease.

---

Volume 177 May 1993 1461-1468
with hen egg white lysozyme (HEL) display at their surface antigenic peptide–class II complexes able to stimulate, in the absence of any further antigen addition, HEL peptide-specific, class II–restricted T cell hybridomas. Co-administration of antigen and MHC class II–binding peptide competitors selectively inhibits the in vivo formation of antigenic complexes and prevents antigen presentation by LNC to class II–restricted T cells, indicating competitive blockade of class II molecules in vivo (14). MHC class II blockade can be induced by administering MHC antagonists either in a depot (9, 14, 15) or in soluble form (16), and this could represent a promising approach to selectively induce immunosuppression of undesired immune responses (17). However, several points still need to be addressed to evaluate the practical feasibility of this form of immunointervention.

In the present paper we have examined the effect of MHC class II blockade on the in vivo antibody responses to T cell–dependent antigens. Injection of a nonimmunogenic MHC class II–binding self-peptide at the time of antigen priming can inhibit both primary and secondary antibody responses to protein antigens. This inhibition is associated with decreased formation of antigenic peptide–MHC class II complexes in vivo, resulting in inhibition of class II–restricted T cell proliferation. All antibody isotypes are equally inhibited, suggesting that MHC blockade inhibits activation of both Th1- and Th2-type T helper cells. As for T cell activation, the inhibition of antibody responses is selective for the MHC class II molecules binding the competitor peptide, and its extent depends on the molar ratio between antigen and competitor.

Materials and Methods

Mice. 2– to 3-mo-old DBA/2, BALB/c, C3H, B10.D2 (Iffa Credo, L'Arbelle, France) and B10.A(4R) (Olaco Bicester, UK) mice of either sex were used.

Antigen. HEL, recrystallized three times, and bovine RNase were obtained from Sigma Chemical Co. (St. Louis, MO). Peptides were synthesized by the solid-phase method on phenylacetamido-carbonate-bicarbonate buffer, pH 9.6. After washing with PBS, Dickinson & Co., Oxnard, CA) were incubated overnight at 4°C in a humidified atmosphere of 5% CO2 in air and were pulsed 10 h before harvesting with 1 μCi [3H]Tdr (40 Ci/nmol; the Radiochemical Center, Amersham, UK). Incorporation of [3H]Tdr was measured by liquid scintillation spectrometry.

Immunizations. Mice were immunized subcutaneously at the tail base and into the hind footpads, or by intraperitoneal injection with the indicated amount of antigen emulsified in IFA or CFA containing H37Ra mycobacteria (Difco Laboratories, Inc., Detroit, MI). For the induction of secondary antibody responses, mice were challenged by injecting intraperitoneally 100 μg/mouse of soluble antigen in PBS.

ELISA. Polyvinyl microtiter plates (Falcon model 3012; Becton Dickinson & Co., Oxnard, CA) were incubated overnight at 4°C with 50 μl/well of HEL or RNase at 10 μg/ml in 60 mM sodium carbonate–bicarbonate buffer, pH 9.6. After washing with PBS, the plates were blocked by incubation with PBS containing 1% BSA for 1 h at 37°C. Plates were then washed three times with PBS containing 0.1% Tween 20 (PBS-Tw). Appropriately diluted sera (50 μl/well) were titrated in PBS-Tw containing 1% BSA (PBSA-Tw), and incubated for 90 min at 37°C. Plates were then washed and incubated for 1 h at 37°C with a mixture (100 ng/ml each) of the following biotin-conjugated goat anti–mouse isotype-specific antibodies (Southern Biotechnology Associates Inc., Birmingham, AL): anti-IgM, -IgG1, -IgG2a, -IgG2b, and -IgG3. After washing, the bound antiisotypic antibodies were revealed by an additional 1-h incubation with alkaline phosphatase–conjugated streptavidin (Jackson Immunoresearch Laboratories, Inc., West Grove, PA) diluted 1:20,000. The plates were washed again and incubated with the developing substrate p-Nitrophenylphosphate disodium (Sigma Chemical Co.) in diethanolamine buffer, pH 9.6 (100 μl/well). The reaction was stopped by adding 50 μl/well NaOH 3 N, and absorbance was read at 405 nm using an automated microplate ELISA reader (Titertek Multiskan® MCC/340; Flow Laboratories, Helsinki, Finland). Standard curves were generated using pooled sera from mice immunized with the corresponding antigen. The amount of HEL-specific antibodies was calculated using affinity-purified anti-HEL antibodies and results expressed as serum antibody concentration in mg/ml. The serum anti-RNase antibody concentration was expressed as arbitrary U/ml. Anti-HEL and -RNase IgM, IgG1, IgG2a, IgG2b isotypes were determined as described above using biotinylated isotype-specific antibodies. Standard curves were obtained using calibrated serum pools revealed with antiisotypic developing reagents, and results expressed as relative U/ml.

T Cell Proliferation Assay. LNs draining the injection sites were removed, and 4 × 106 cells/well were cultured in 96-well culture plates (Costar Corp., Cambridge, MA) in synthetic HEL-I medium (Ventrex Laboratories, Portland, ME) supplemented with 2 mM l-glutamine and 50 μg/ml gentamicin (Sigma Chemical Co.) with the indicated antigen concentrations. Cultures were incubated for 3 d in a humidified atmosphere of 5% CO2 in air and were pulsed 10 h before harvesting with 1 μCi [3H]TdR (40 Ci/nmol; the Radiochemical Center, Amersham, UK). Incorporation of [3H]TdR was measured by liquid scintillation spectrometry.

Assay for Antigen Presenting Activity of LNC from HEL-primed Mice. The antigen presenting activity of LNC from HEL-primed mice was assessed as previously described (14) using the following T cell hybridomas: ICS5.1 (I-Ak, HEL-64-61) (14); 3B11.1 (I-Ak, HEL-34-45) (Adorini, L., unpublished results); and 1H11.3 (I-Eα, HEL-108-116) (6). Briefly, mice were immunized into the hind footpads with the indicated amount of antigen emulsified in IFA or CFA. 5–6 d later, the draining popliteal LNC were removed, irradiated (2,400 rad), and cultured in triplicate at the indicated cell doses with appropriate HEL-specific T cell hybridomas (5 × 104 cells/well) in 96-well culture plates (Costar Corp.). Culture medium was RPMI 1640 (Gibco, Basel, Switzerland) supplemented with 2 mM l-glutamine, 50 mM 2-ME, 50 μg/ml gentamicin (Sigma Chemical Co.), and 10% FCS (Gibco). After 24 h of culture, 50 μl aliquots of supernatants were transferred to microculture wells containing 104 CTLL cells and, after an additional 24-h incubation, the presence of T cell growth factors, mainly IL-2, was assessed by [3H]Tdr incorporation during the last 4 h of culture. For the anti-Thy-1 cytotoxic treatment, LNC (6 × 104/ml) were incubated with 1.5 μg/ml of anti-Thy-1.2 mAb (Becton Dickinson & Co., Mountain View, CA) for 30 min on ice. After washing, cells were resuspended in rabbit complement (low-tox M®; Cedarlane Laboratories, London, Canada) at a final dilution of 1:12; incubated 45 min at 37°C, washed, and then irradiated. T cell depletion was assessed by cytofluorimetric analysis with biotinylated anti-TCR mAb (18).
Results

**ML46-62 Inhibits the Anti-HEL Antibody Response in H-2^k but Not in H-2^d Mice.** The mouse lysozyme (ML) peptide 46-62 binds strongly to I-A^k molecules but fails to bind to I-E^k, I-A^d, and I-E^d molecules (5, 9, 16). We have previously shown that administration of this peptide selectively blocks, in vivo, T cell activation induced by I-A^k-binding antigenic peptides (9, 14). To examine the effect of MHC class II blockade on T cell-dependent antibody responses, B10.A(4R) mice, expressing only the I-A^k class II molecule, were immunized intraperitoneally with HEL (35 pmoles/mouse) alone, or mixed with either 5 or 0.5 nmoles of ML46-62. The anti-HEL antibody response was quantitated by ELISA at different times after priming. As shown in Fig. 1 A, administration of ML46-62 (5 or 0.5 nmoles/mouse) inhibits almost completely the anti-HEL antibody response. The inhibitory effect was slightly reduced at 14-fold competitor excess over HEL, as compared with 140-fold excess. As expected from its binding specificity, ML46-62 administered at 5 nmoles/mouse to DBA/2 (H-2^d) mice does not affect the anti-HEL antibody response (Fig. 1 B), demonstrating that this peptide is devoid of any nonspecific immunosuppressive properties. Therefore, as for T cell priming in vivo, inhibition of the antibody response by administration of class II-binding competitor peptides is selective for the MHC class II molecules to which the competitor binds, and its extent depends on the molar ratio between antigen and competitor.

**Inhibition of the Primary and Secondary Antibody Response to HEL and RNase, an Antigen Unrelated to the MHC Blocker.** Having shown that ML46-62 is able to selectively block the primary anti-HEL antibody response in B10.A(4R) mice, we tested its ability to inhibit both primary and secondary antibody responses to HEL and to RNase, an antigen unrelated to ML46-62. As shown in Fig. 2, ML46-62 administration induces a 5-10-fold reduction of the primary antibody responses to both protein antigens. This inhibition is long-lasting and can be observed over a period of 20 wk. Upon challenge with the corresponding soluble protein antigens, a 20-fold increase of antigen-specific serum antibody is induced, but in mice injected with ML46-62 at the time of priming, the secondary antibody response was 10-20-fold lower than control responses. This effect is specific since administration of a non-I-A^k-binding peptide (HEL64-77) does not affect the anti-HEL (Fig. 2 A) or the anti-RNase (data not shown) antibody responses. In Fig. 2 B, the competitor peptide was administered in IFA 1 d before immunization with RNase, indicating that separate administration of antigen and competitor also inhibits primary and secondary antibody responses. The results indicate that administration of class II-binding competitor peptides unrelated to the antigen can efficiently inhibit both primary and secondary in vivo antibody responses induced by Th whose activation is restricted by the blocked class II molecule.

**Effect of MHC Blockade on Anti-HEL and Anti-RNase Ig Isotypes.** The inhibitory effect of ML46-62 was tested, so far, by measuring the whole humoral response. We next determined whether different antigen-specific Ig isotypes were all similarly affected. Results in Table 1 show that, in the primary and secondary anti-HEL antibody responses, IgG1 is the dominant isotype, and that all Ig isotypes measured are inhibited by administration of ML46-62. Conversely, injection of HEL64-77 does not significantly affect any of the anti-HEL Ig isotypes. This inhibition is more pronounced in the secondary response, and it is higher for the dominant isotype. Similar results are obtained measuring anti-RNase Ig isotypes. In this case, unlike HEL, the primary antibody response also includes IgM antibodies. In the primary response, IgG1 and IgM are predominantly reduced, whereas in the secondary response, all isotypes are inhibited. Collectively, these results indicate that inhibition of antibody response by MHC class II blockade affects all Ig isotypes. Since IgG1 are

![Figure 1](image1.jpg)

**Figure 1.** Inhibition of the primary anti-HEL antibody response by administration of ML46-62. B10.A(4R) (A) or DBA/2 (B) mice were immunized intraperitoneally with CPA only (A) or with an emulsion containing 35 pmoles HEL alone (C), or mixed with 5 nmoles (C) or 0.5 nmoles (D) of ML46-62. The anti-HEL antibody response was measured by quantitative ELISA in individual mice at the indicated days after priming by ELISA. Data are expressed as mean ± SEM anti-HEL serum antibody concentration (ng/ml) from three to four mice per group.

![Figure 2](image2.jpg)

**Figure 2.** Inhibition of primary and secondary anti-HEL and anti-RNase antibody responses by administration of ML46-62. (A) B10.A(4R) mice were immunized intraperitoneally with 35 pmoles HEL alone (O), or mixed with either ML46-62 (●) or HEL64-77 (Δ). (5 nmoles/mouse). (B) Mice were injected 1 d before antigen priming with IFA alone (O) or with 30 nmoles ML46-62 (●) in IFA, and then immunized with RNase, 210 pmoles/mouse in CFA. Mice were then challenged with the corresponding soluble antigen (100 μg/mouse) about 20 wk after priming (arrows). Results are expressed as mean anti-HEL antibody concentration (ng/ml) from three to four mice per group, or as mean ± SEM anti-RNase antibody serum concentration expressed in arbitrary mU/ml from six mice per group.
**Table 1.** ML46-62 Inhibits Different Antibody Isotypes Induced by HEL and RNase in B10.A(4R) Mice

| Antigen | Competitor | Challenge | Ig M | IgG1 | IgG2a | IgG2b |
|---------|------------|-----------|------|------|-------|-------|
| HEL     | -          | -         | <5   | 1,915 ± 318 | 34 ± 29 | 196 ± 101 |
| HEL     | ML46-62    | -         | <5   | 153 ± 91   | 5 ± 3.2 | 11.3 ± 6.6 |
| HEL     | HEL64-77   | -         | <5   | 1,762 ± 722 | 9.1 ± 4.5 | 119 ± 18 |
| HEL     | -          | HEL       | <5   | 14,840 ± 6,162 | 291 ± 199 | 874 ± 507 |
| HEL     | ML46-62    | HEL       | <5   | 724 ± 125  | 42 ± 24 | 92 ± 63 |
| HEL     | HEL64-77   | HEL       | <5   | 10,237 ± 4,004 | 171 ± 122 | 1,175 ± 597 |
| RNase   | -          | -         | 13.5 ± 5.8 | 1,169 ± 231 | 117 ± 45 | 196 ± 71 |
| RNase   | ML46-62    | -         | 5.3 ± 2.2 | 335 ± 110  | 83 ± 19 | 151 ± 43 |
| RNase   | -          | RNase     | <5   | 14,534 ± 6,212 | 1,443 ± 568 | 1,908 ± 629 |
| RNase   | ML46-62    | RNase     | <5   | 627 ± 224  | 316 ± 142 | 554 ± 329 |

Sera from the experiment described in Fig. 2 were tested for anti-HEL and anti-RNase Ig isotypes by ELISA, as described in Materials and Methods. Results shown refer to antibody isotypes detected in sera obtained at peak primary (day 31 for HEL, day 43 for RNase) and secondary (day 9 for HEL, day 21 for RNase) antibody responses. Results are expressed as serum antibody concentration (U/ml) ± SEM from three to five mice per group.

Predominantly induced by Th2 and IgG2a/IgG2b by Th1 cells (19-21), MHC blockade appears to inhibit the helper function of both Th cell subsets.

**Lack of Inhibition of Anti-HEL Antibody Response by Administration of ML46-62 in Primed Mice.** We next analyzed the effect of administering ML46-62 1 d before immunization or 10 d after priming with HEL. As shown in Fig. 3 (D and E), administration to B10.A(4R) mice of the competitor peptide emulsified together with HEL, or in a separate depot 1 d before HEL priming, strongly inhibits the entire anti-HEL antibody response, as compared with controls (Fig. 3, A and B). Conversely, ML46-62 administered 10 d after HEL-CFA priming does not affect the ongoing anti-HEL antibody response (Fig. 3 F). Similar results were obtained when ML46-62 was administered 3 d after HEL priming (data not shown). These results confirm that the coadministration of antigen and competitor is not a prerequisite for inhibition of the antibody response, as previously shown with RNase (Fig. 2 B). It is interesting that once the immune response is initiated, the competitor peptide has no effect, a result consistent with the MHC blockade model.

**Direct Evidence for MHC Blockade Induced In Vivo by ML46-62.** To analyze the mechanisms involved in MHC blockade, we recently described an ex vivo system to detect complexes between antigenic peptides and MHC class II molecules generated in vivo (14). Using this assay we tested the ability of ML46-62 to selectively inhibit in vivo formation of antigenic complexes between I-Ak class II molecules and the two dominant HEL peptides 46-61 and 34-45 derived from HEL processing (22). H-2k (C3H and B10.A[4R]) and H-2d (BALB/c and B10.D2) mice were immunized with HEL or with an emulsion containing HEL and ML46-62 either in IFA or in CFA. 5 d later, irradiated LNC were tested for their ability to activate the I-Ak-restricted T cell hybridomas 1C5.1 (HEL46-61/Ak) and 3Bl1.1 (HEL34-45/Ak) or the I-Eα-restricted T cell hybridoma 1H11.3 (HEL108-116/Eα). As shown in Fig. 4, coinjection of HEL and the I-Ak-binding peptide ML46-62 markedly inhibits the antigen presenting activity of LN APC to the I-Ak-restricted T cell hybridomas, specific for HEL peptides 46-61 and 34-45, in both
The proliferation of CTLL was 545 cpm. Data were pooled, treated with anti-Thy-1 mAb plus C°C, irradiated, and 10^6 cells/well cultured with the T cell hybridomas: 3Bl1.1 (A and D), 1C5.1 (B, E), or 1Hll.3 (C). After 24 h, IL-2 production was measured by adding 50 µl aliquots of culture supernatant to 10^6 CTLL for an additional 24 h. [3H]Thymidine (1 µCi/well) was added during the last 5 h of culture. IL-2 production induced in T cell hybridomas by addition of 3 µM HEL to 2.5 x 10^3 LNC/well from mice injected with HEL alone or mixed with the competitor peptide were respectively (cpm): 117,031, 129,413 (A); 128,927, 95,432 (B); 211,492, 218,803 (C); 105,126, 87,499 (D); and 100,203, 118,098 (E). Data are presented as mean cpm of thymidine incorporation from triplicate cultures. Background proliferation of CTLL cells was 258 cpm.

Figure 4. Selective inhibition of I-A<sub>k</sub>-restricted antigen presentation by ML46-62. B10.A(4R) (A and D), C3H (B and E), and BALB/c (C) mice were immunized in IFA with 3 nmoles HEL alone (□) or mixed with 100 nmoles ML46-62 (●). 5 d later, LNC from three mice were pooled, irradiated, and cultured with the T cell hybridomas: BALB/c (C3H1.1 (A and C), 1C5.1 (D and E), or 1Hll.3 (C). After 24 h, IL-2 production was measured by adding 50 µl aliquots of culture supernatant to 10^6 CTLL for an additional 24 h. [3H]Thymidine (1 µCi/well) was added during the last 5 h of culture. IL-2 production induced in T cell hybridomas by addition of 3 µM HEL to 2.5 x 10^3 LNC/well from mice injected with HEL alone or mixed with the competitor peptide were respectively (cpm): 117,031, 129,413 (A); 128,927, 95,432 (B); 211,492, 218,803 (C); 105,126, 87,499 (D); and 100,203, 118,098 (E). Data are presented as mean cpm of thymidine incorporation from triplicate cultures. Background proliferation of CTLL cells was 258 cpm.

Figure 5. Inhibition of antigen presentation is not due to T cells. B10.A(4R) (A, B) and B10.D2 (C) mice were immunized with CFA containing 3 nmoles HEL alone (□) or mixed either with 100 nmoles ML46-62 (●) or 100 nmoles HEL64-77 (□). 5 d later, LNC from two mice were pooled, treated with anti-Thy-1 mAb plus C°C, irradiated, and 10^6 cells/well cultured with the T cell hybridomas: 3Bl1.1 (A), 1C5.1 (B), and 1Hll.3 (D). The experiment was then continued as in Fig. 4. Data are shown as mean cpm ± SEM from triplicate cultures. Background proliferation of CTLL was 545 cpm.
The mouse self-lysozyme peptide ML46-62 binds to I-A\(\kappa\) molecules (5, 9, 16) and it selectively inhibits, when coinjected with antigen, priming of I-A\(^\kappa\)-restricted, antigen-specific T cells (9). We have coinjected ML46-62 together with protein antigens, HEL or RNase, in B10.A(4R) mice, expressing only I-A\(^\kappa\) as MHC class II molecules. Therefore, in this mouse strain, the T cell–dependent antibody response to protein antigens such as HEL or RNase can only be mediated by I-A\(^\kappa\)-restricted T helper cells. In the case of HEL, different immunodominant T cell epitopes generated by HEL processing are presented by I-A\(^\kappa\) molecules. Three major immunodominant HEL determinants recognized by I-A\(^\kappa\)-restricted T cells are included in the HEL sequences 46-61 (22), 34-45 (22, 24), and 112-129 (25), and a minor one is located in the HEL region 25-43 (25). In the case of RNase, an immunodominant epitope able to induce I-A\(^\kappa\)-restricted T cells is located in the region 43-56 (26). Since all these epitopes are potentially able to induce T helper cells, blocking the antigen-presenting function of the I-A\(^\kappa\) molecule should result in inhibition of the antiprotein antibody response only if T cell responses to all these determinants are blocked. Results in the present paper demonstrate that this is the case: coinjection of ML46-62 and HEL in B10.A(4R) mice inhibits the entire anti-HEL antibody response. Similarly, coinjection of ML46-62 and RNase, an antigen unrelated to this class II–binding peptide, results in inhibition of the entire anti-RNase antibody response.

Administration of class II–binding peptides could inhibit in vivo T cell activation by antigen (23, 27-32) or MHC-related mechanisms (10, 11, 13, 14). Several lines of evidence indicate that the mechanism leading to inhibition of T cell–dependent antibody responses by administration of ML46-62 is in vivo blockade of MHC class II molecules and a consequent decrease in antigen-specific T cell responses. First, this self-peptide does not activate mouse T cells (9), therefore a direct blockade of T cell receptors by ML46-62 is unlikely. Second, since ML46-62 does not induce a T cell response, the inhibition of antibody production cannot be attributed to clonal dominance induced by the competitor peptide. Third, ML46-62 inhibits efficiently the antibody response induced by RNase, an unrelated protein antigen, indicating that inhibition of the antibody response does not result from induction of T cell tolerance or antigen-specific suppressor T cells. Fourth, injection of ML46-62 selectively inhibits antibody responses induced by T helper cells restricted by I-A\(^\kappa\), as expected from its binding specificity (5, 9, 16), thus excluding a possible induction of nonspecific suppressive mechanisms. Finally, administration of ML46-62 after antigen priming does not inhibit the ongoing antibody response, demonstrating its capacity to prevent T cell activation when coinjected with antigen, but not when injected subsequently, as predicted from the MHC blockade model.

MHC blockade as the mechanism leading to inhibition of antibody responses in vivo is also indicated by the concomitant in vivo inhibition of complexes formed between peptides derived from antigen processing and class II molecules. In addition to the 46-61 epitope (14), the most abundant naturally processed HEL epitope bound to I-A\(^\kappa\) molecules (33), HEL34-45–I-A\(^\kappa\) complexes formed in vivo are

**Discussion**

Induction of immunosuppression by MHC class II antagonists has been demonstrated in a variety of experimental systems, by examining their effect on T cell activation, in vivo, either in response to conventional antigens (9) or in autoimmune disease models (10–13). However, MHC blockade has been evaluated mostly by its effect on T cell proliferation, and this may not reflect the entire immune response (23). Therefore, we have examined the effect of administering a class II–binding peptide on induction of T cell–dependent antibody responses to protein antigens.

The mouse self-lysozyme peptide ML46-62 binds to I-A\(^\kappa\) molecules (5, 9, 16) and it selectively inhibits, when coinjected with antigen, priming of I-A\(^{\kappa}\)-restricted, antigen-specific T cells (9). We have coinjected ML46-62 together with protein antigens, HEL or RNase, in B10.A(4R) mice, expressing only I-A\(^{\kappa}\) as MHC class II molecules. Therefore, in this mouse strain, the T cell–dependent antibody response to protein antigens such as HEL or RNase can only be mediated by I-A\(^{\kappa}\)-restricted T helper cells. In the case of HEL, different immunodominant T cell epitopes generated by HEL processing are presented by I-A\(^{\kappa}\) molecules. Three major immunodominant HEL determinants recognized by I-A\(^{\kappa}\)-restricted T cells are included in the HEL sequences 46-61 (22), 34-45 (22, 24), and 112-129 (25), and a minor one is located in the HEL region 25-43 (25). In the case of RNase, an immunodominant epitope able to induce I-A\(^{\kappa}\)-restricted T cells is located in the region 43-56 (26). Since all these epitopes are potentially able to induce T helper cells, blocking the antigen-presenting function of the I-A\(^{\kappa}\) molecule should result in inhibition of the antiprotein antibody response only if T cell responses to all these determinants are blocked. Results in the present paper demonstrate that this is the case: coinjection of ML46-62 and HEL in B10.A(4R) mice inhibits the entire anti-HEL antibody response. Similarly, coinjection of ML46-62 and RNase, an antigen unrelated to this class II–binding peptide, results in inhibition of the entire anti-RNase antibody response.
readily detectable on LN APC. By monitoring complexes of both epitopes, we have demonstrated that administration of ML46-62 selectively inhibits the capacity of I-Ak molecules to present antigen to T cells. Inhibition of antigen presentation is associated with inhibition of I-Ak-restricted T cell proliferation to all immunodominant HEL epitopes tested, demonstrating the functional role of MHC blockade. Thus, inhibition of T cell–dependent antibody responses by administration of ML46-62 correlates with inhibition of antigenic complex formation in vivo and with inhibition of T cell priming, indicating MHC blockade as the mechanism leading to inhibition of antibody responses in vivo. This was previously postulated in a transgenic model where autoantibody production against the neo-self hepatitis B e antigen (HBeAg) was induced by a nontolerogenic T cell epitope of HBeAg and inhibited upon coadministration of an unrelated exogenous peptide (34).

Two types of T helper cells, Th1 and Th2, have been described in the mouse, based on their different lymphokine production patterns (35). Th1 cells, which produce IL-2 and IFN-γ, preferentially induce synthesis of antibodies expressing the IgG2a isotype. Conversely, Th2 cells, producing IL-4, -5, and -10, mainly elicit antibody responses of IgG1 and IgE isotype and cause B cell proliferation and differentiation (19–21, 36). Based on the fact that IgG1 and IgG2a/IgG2b isotypes were inhibited, as well as T cell proliferative responses, it is likely that MHC blockade inhibits activation of Th1- and Th2-type helper cells equally well. Therefore, the inhibition of clonal expansion of Th cells by blocking the initial antigen–TCR interaction seems to affect both types of Th cells, preventing B cell proliferation and differentiation as well as generation of antigen-specific memory cells. This is exemplified by the inhibition of the secondary immune response where the unresponsiveness in B cells to soluble antigen is likely to arise both from lack of antigen-specific T cell help, mainly of Th2-type, and lack of antigen-specific memory B cells able to endocytose soluble antigen and to present efficiently antigenic peptide–MHC complexes to primed T cells (37).

Tolerance induction by antigens administered in nonimmunogenic form can also inhibit T cell activation in vivo. It has been recently shown that antigen-specific unresponsiveness induced by pretreatment with aqueous antigen selectively tolerizes Th1-like but not Th2-like T cells (38, 39). Since human CD4+ T cell clones specific for allergenic and helminthic antigens, exhibit Th2-like lymphokine production profiles (40), in these cases tolerance induction may not affect pathogenic T cells. Conversely, as discussed above, MHC blockade can effectively inhibit the helper function of both Th1- and Th2-type cells.

In conclusion, we have demonstrated that administration of MHC class II antagonists can inhibit the induction of T cell–dependent primary and secondary antibody responses. Inhibition of in vivo antibody responses is associated to prevention of complex formation between antigenic peptides and class II molecules indicating MHC blockade as the mechanism hindering T helper cell activation. Therefore, MHC class II antagonists may induce selective immunosuppression in HLA-associated autoimmune diseases (17), including diseases, like myasthenia gravis, where autoantibodies have a direct pathogenic role (41).

J.-C. Guéry was supported in part by fellowships from the Fondation pour la Recherche Médicale and the European Science Foundation (1991).

Address correspondence to Dr. Luciano Adorini, Roche Milano Ricerche, Via Olgettina, 58, I-20132 Milano, Italy. J.-C. Guéry is currently on a leave of absence from INSERM U28, Hôpital Broussais, Paris, France.

M. Neagu is currently at Cantacuzino Institute, Bucharest, Romania.

Received for publication 9 February 1993.

References

1. Möller, G. 1988. Antigen processing. Immunol. Rev. 106:1.
2. Sette, A., and H.M. Grey. 1992. Chemistry of peptide interaction with MHC proteins. Curr. Opin. Immunol. 4:79.
3. Werdelin, O. 1982. Chemically related antigens compete for presentation by accessory cells to T cells. J. Immunol. 129:1883.
4. Rock, K.L., and B. Benacerraf. 1984. Selective modification of a private I-A allostimulating determinant(s) upon association of antigen with an antigen-presenting cell. J. Exp. Med. 159:1238.
5. Babbitt, B.P., G. Matsueda, E. Haber, E.R. Unanue, and P.M. Allen. 1986. Antigenic competition at the level of peptide-Ia binding. Proc. Natl. Acad. Sci. USA. 83:4509.
6. Guillet, J.-G., M.-Z. Lai, T.J. Briner, J.A. Smith, and M.L. Gefter. 1986. Interaction of peptide antigens and class II major histocompatibility antigens. Nature (Lond.). 324:260.
7. Buus, S., A. Sette, S.M. Colon, C. Miles, and H.M. Grey. 1987. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (Wash. D.C.). 235:1353.
8. Adorini, L., A. Sette, S. Buus, H.M. Grey, M. Darsley, PV. Lehmann, G. Doria, Z.A. Nagy, and E. Appella. 1988. Interaction of an immunodominant epitope with Ia molecules in T-cell activation. Proc. Natl. Acad. Sci. USA. 85:5181.
9. Adorini, L., S. Muller, F. Cardinaux, PV. Lehmann, F. Falconi, and Z.A. Nagy. 1988. In vivo competition between self peptides and foreign antigens in T cell activation. Nature (Lond.). 334:623.
10. Lamont, A.G., A. Sette, R. Fujinami, S.M. Colon, G. Miles,
11. Gautam, A.M., C.I. Pearson, A.A. Sinha, D.E. Smilek, L. Steinman, and H.O. McDevitt. 1992. Inhibition of experimental autoimmune encephalomyelitis by a nonimmunogenic non-self peptide that binds to I-A\(^\alpha\) molecules. J. Immunol. 145:1687.

12. Wauben, M.H.M., C.J.P. Boog, R. van der Zee, I. Joosten, A. Schriefl, and W. van Eden. 1992. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone. J. Exp. Med. 176:667.

13. Smith, S.C., and P.M. Allen. 1991. Myosin-induced acute myocarditis is a T cell-mediated disease. J. Immunol. 147:2141.

14. Guéry, J.-C., A. Sette, J. Leighton, A. Dragomir, and L. Adorini. 1992. Selective immunosuppression by administration of MHC class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation. J. Exp. Med. 175:1345.

15. Lamont, A.G., M.F. Powell, S.M. Colon, G. Miles, H.M. Grey, and A. Sette. 1990. The use of peptide analogs with improved stability and MHC binding capacity to inhibit antigen presentation in vitro and in vivo. J. Immunol. 144:2493.

16. Muller, S., L. Adorini, A. Juretic, and Z.A. Nagy. 1990. Selective inhibition of T cell activation by class II MHC-binding peptides administered in soluble form. J. Immunol. 145:4006.

17. Adorini, L., J.-C. Guéry, and S. Trembleau. 1992. Approaches toward peptide-based immunotherapy of autoimmune diseases. Springer Semin. Immunopathol. 14:187.

18. Kubo, R.T., W. Born, J.W. Kappler, P. Marrack, and M. Pigeon. 1989. Characterization of monoclonal antibody which detects all murine αβ T cell receptors. J. Immunol. 142:2736.

19. Snapper, C.M., and W.E. Paul. 1987. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science (Wash. DC). 236:944.

20. Finkelman, F.D., J. Holmes, I.M. Katona, J.F. Urban, M.P. Beckmann, L.S. Park, K.A. Shooley, R.L. Coffman, T.R. Mosmann, and W.E. Paul. 1990. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8:303.

21. Burstein, H.J., R.I. Tepper, P. Leder, and A.K. Abbas. 1991. Humoral immune functions in IL-4 transgenic mice. J. Immunol. 147:2950.

22. Allen, P.M., B.P. Babbit, and E.R. Unanue. 1987. T cell recognition of lysozyme: the biochemical basis of presentation. Immunol. Rev. 98:171.

23. Evaold, B.D., and P.M. Allen. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science (Wash. DC). 252:1308.

24. Gammon, G., H.M. Geyser, R.J. Apple, E. Pickett, M. Palmer, A. Ametani, and E.E. Sercarz. 1991. T cell determinant structure: cores and determinant envelopes in three mouse major histocompatibility complex haplotypes. J. Exp. Med. 173:609.

25. Adorini, L., E. Appella, G. Doria, and Z.A. Nagy. 1988. Mechanisms influencing the immunodominance of T cell determinants. J. Exp. Med. 168:2091.

26. Lorenz, R.G., A.N. Tyler, and P.M. Allen. 1988. T cell recognition of bovine ribonuclease. Self/non-self discrimination at the level of binding to I-A\(^\beta\) molecule. J. Immunol. 141:4124.

27. Sercarz, E., and U. Krzych. 1991. The distinct specificity of antigen-specific suppressor T cells. Immunol. Today. 12:111.

28. Ria, F., B.M.C. Chan, M.T. Scherer, J.A. Smith, and M.L. Gefter. 1990. Immunological activity of covalently linked T-cell epitopes. Nature (Lond.). 343:381.

29. Janeway, C.A. 1989. Immunotherapy by peptides? Nature (Lond.). 341:482.

30. Wraith, D.C., D.E. Smilek, D.J. Mitchell, L. Steinman, and H.O. McDevitt. 1989. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell. 59:247.

31. Sakai, K., S.S. Zamvil, D.J. Mitchell, S. Hodgkinson, J.B. Rothbard, and L. Steinman. 1989. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex protein. Proc. Natl. Acad. Sci. USA. 86:9470.

32. De Magistris, T.M., J. Alexander, M. Coggeshall, A. Altman, F.C.A. Gaeta, H.M. Grey, and A. Sette. 1992. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell. 68:625.

33. Nelson, C.A., R.W. Roof, D.W. McCourt, and E.R. Unanue. 1992. Identification of the naturally processed form of hen egg white lysozyme bound to the murine major histocompatibility complex class II molecule I-A\(^\alpha\). Proc. Natl. Acad. Sci. USA. 89:7380.

34. Milich, D.R., A. McLachlan, A.K. Raney, R. Houghten, G.B. Thornton, T. Maruyama, J.L. Hughes, and J.E. Jones. 1991. Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with non-self peptides. Proc. Natl. Acad. Sci. USA. 88:4348.

35. Mosmann, T.R., and R.L. Coffman. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.

36. Abbas, A.K., M.E. Williams, H.J. Burstein, T.-L. Chang, P. Bossu, and A.H. Lichtman. 1991. Activation and functions of CD4\(^+\) T cell subsets. Immunol. Rev. 123:5.

37. Lanzeretvicha, A. 1990. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu. Rev. Immunol. 8:773.

38. Burstein, H.J., C.M. Shea, and A.K. Abbas. 1992. Aqueous autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with non-self peptides. Proc. Natl. Acad. Sci. USA. 88:4348.

39. De Wit, D., M. Van Mechelen, M. Ryleandt, A.C. Figueiredo, D. Abramowicz, M. Goldman, H. Bazin, J. Urbain, and O. Leo. 1992. The injection of deaggregated gamma globulins in adult mice induces antigen-specific unresponsiveness of T helper type 1 but not type 2 lymphocytes. J. Exp. Med. 175:9.

40. Del Prete, G., M. De Carli, C. Mastromauro, R. Biagiotti, D. Macchia, P. Falagiani, M. Ricci, and S. Romagnani. 1991. Purified protein derivative of mycobacterium tuberculosis and excretory-secretory antigens(s) of toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J. Clin. Invest. 88:346.

41. Lindstrom, J., D. Shelton, and Y. Fujii. 1988. Myasthenia gravis. Adv. Immunol. 42:233.